Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

ASH 2024 Summary: Highlights in Adult ALL and Implications for Pract…

2024 ASH Annual Meeting Insights Hub

R. Cassaday

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Revumenib for KMT2A+ R/R Acute Leukemias - Drug Overview and Clinica…

OncoPharm

J. Bossaer

ASH 2024 Summary: Highlights in Ph+ ALL

2024 ASH Annual Meeting Insights Hub

F. Haddad

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Vanderbilt University Medical Center (VUMC)

A. Jallouk

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Fred Hutchinson Cancer Center

R. Cassaday

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

2024 Review of Frontline Treatment in ALL

Louisville Hematology Highlights

N. Short

Treating Adult B-ALL: CAR-T vs. Bispecifics vs. Monoclonals

Marlise R. Luskin

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

Rush University Medical Center

E. Bhaimia

FDA Approved First Oral Solution of Imatinib

Winship Cancer Institute - Emory University

A. Abousaud

Immunotherapies in Acute Leukemias: 2024 Update

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

C. Lai

Allo-HSCT Conditioning Regimens: Current Status and Future Directions

Rush University Medical Center

C. Brunstein

ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based GvHD Pr…

2024 ASCO® Annual Meeting Insights Hub

M. Al Malki

Considering Venetoclax in AML and ALL - Which Patients and Why

Marina Konopleva